Live Breaking News & Updates on Xylem investment

Stay informed with the latest breaking news from Xylem investment on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Xylem investment and stay connected to the pulse of your community

Wockhardt's R&D prowess attracts marquee investors Madhusudan Kela, Prashant Jain

Wockhardt has two molecules — Nafithromycin (WCK 4873) for treating pneumonia and WCK 5222 for urinary tract infection, in development phases, with launched lined up for FY25 and FY26

India , Prashant-jain , Madhusudan-kela , Pfizer , Prudential , Tata-indian-opportunities-fund , Mirae-asset , Habilf-khorakiwala , Vineet-gala , Xylem-investment , Wockhardt , Ip